Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.

• Submission of report completes phase 1 of Ucore’s contract with the U.S. Department of Defense to demonstrate the technical capabilities of its RapidSX rare earth separation platform.
• The DoD has identified rare earth processing as a strategic priority under its industrial base strengthening initiatives.
• RapidSX combines aspects of conventional solvent extraction with modern column-based design to enable faster throughput, reduced footprint and potentially lower capital and operating costs.

Submitting a final technical report to a federal partner is more than a procedural step; it signals measurable progress in translating advanced technology into national supply chain capability. Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) recently announced that it has submitted its final phase 1 report to the U.S. Department of Defense [DoD] under its RapidSX(TM) rare earth processing project, marking a significant milestone in the company’s effort to commercialize its separation technology and support domestic rare earth independence.

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) s a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America. Originally founded in 2006 as a mineral exploration company, Ucore has since evolved into a processing technology innovator focused on commercializing its proprietary RapidSX™ platform under a $18.4 million contract from the U.S. Department of Defense, with additional support from Natural Resources Canada. The company’s flagship deployment is the Louisiana Strategic Metals Complex (“SMC”), with additional SMCs planned to follow.

Ucore’s mission is to help reestablish a domestic REE supply chain by offering competitive, modular processing solutions that reduce dependence on China. Supported by government funding, private capital, and engineering partnerships, Ucore aims to meet growing demand for rare earth oxides in electric vehicles, defense systems, and advanced energy technologies.

The company is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Separation Technology

RapidSX™ is Ucore’s proprietary rare earth separation platform, delivering three times faster processing than traditional solvent extraction (SX) methods. Its current demonstration program in Kingston, Ontario, is being conducted under contract with the U.S. Department of Defense to prove commercial readiness for processing both heavy and light REEs. The project is also supported by Natural Resources Canada.

RapidSX™ employs a column-based design that eliminates the need for powered mixer-settlers, enabling a smaller facility footprint, quicker commissioning, and lower CAPEX and OPEX. The platform is adaptable to light and heavy REE feedstocks and is structured for modular scale-up.

The 52-stage RapidSX™ Commercial Demonstration Plant in Kingston, Ontario—operated in partnership with Kingston Process Metallurgy—has logged thousands of runtime hours and is currently processing rare earth feedstock further to the company’s U.S. Department of Defense contract. In January 2025, Ucore secured a $500,000 non-dilutive grant from Ontario’s Critical Minerals Innovation Fund to support the advancement of the Kingston facility and, in the words of Ontario Mines Minister George Pirie, “build a secure supply chain ready to fuel the technologies of tomorrow.”

Strategic Metals Complex – Louisiana

Ucore has selected an 80,800-square-foot brownfield site within the England Airpark in Alexandria, Louisiana, as the location for its first commercial rare earth refining facility. The Louisiana SMC is expected to scale from 2,000 tonnes per annum (TPA) of total rare earth oxides initially to 5,000 TPA, with potential to ultimately reach 7,500 TPA.

The facility benefits from Foreign Trade Zone (FTZ) status, reducing tariff burdens on imported inputs and enhancing logistics efficiency. In addition to these structural advantages, the state of Louisiana has outlined an incentive package valued at $15 million, including a $900,000 infrastructure grant and $360,000 in additional local support. The project is expected to create 100 family-wage jobs and has received strong support from federal and state officials.

To date, Ucore has secured $2.3 million in milestone payments under its $18.4 million OTA award from the U.S. Department of Defense. In early 2024, the company also secured C$2.16 million in private investment from Hondo Private Equity to support its commercialization efforts.

Bokan-Dotson Ridge REE Project – Alaska

Ucore maintains 100% ownership of the Bokan-Dotson Ridge heavy REE project in Southeast Alaska. A Preliminary Economic Assessment was completed in January 2013. The Alaska Industrial Development and Export Authority (AIDEA) has authorized $145 million in bond financing under SB99 (2014) to support future development.

While Bokan remains a long-term asset, Ucore continues to advance it at a measured pace, complementing its near-term focus on commercial rare earth refining and oxide production at the Louisiana SMC.

Market Opportunity

According to Grand View Research, the global rare earth elements market was estimated at $3.95 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market outlook remains strong, fueled by the growing demand for permanent magnets and catalysts in the automotive sector.

In March 2025, President Trump invoked the Defense Production Act to prioritize domestic critical mineral production, signaling a national mandate to reduce reliance on “hostile foreign powers’ mineral production.” One month later, the Chinese government enacted immediate export restrictions on seven key rare earth elements, including dysprosium and terbium, further intensifying pressure on Western nations to develop secure and independent supply chains. This underscores the strategic value of Ucore’s domestic separation infrastructure.

Leadership Team

Pat Ryan, P.Eng., Chairman and CEO, is the founder of Neocon International, a leading automotive OEM supplier. He brings over 25 years of experience in global supply chain innovation and has led Ucore since 2014 in its strategic pivot toward rare earth processing.

Peter Manuel, Vice President, CFO & Corporate Secretary, has served as Ucore’s financial lead for 14 years. Trained as a Chartered Accountant, with extensive experience across Canada, England, and Ireland, Mr. Manuel has advised public and private entities on strategic planning, treasury, and assurance.

Michael Schrider, MEng, P.E., Vice President & COO, is a multidisciplinary engineer with over 30 years of experience. He founded and operated engineering firms SAi and ABD and has overseen all phases of Ucore’s technical development since 2016.

Geoff Atkins, Vice President of Business Development, has 30 years of mining experience and was instrumental in advancing both Lynas’ Mt. Weld and Vital Metals’ Nechalacho REE operations. He brings deep operational knowledge and leads feedstock strategy at Ucore.

Ucore Rare Metals Inc. (OTCQX: UURAF), closed Tuesday's trading session at $5.09, up 6.263%, on 435,806 volume. The average volume for the last 3 months is 297,690 and the stock's 52-week low/high is $0.5455/$10.69.

Recent News

• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) - Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Key Federal Milestone for RapidSX Platform
• EnergyNewsBreaks - Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Provides Update on Samarium and Gadolinium Supply Initiative
• DefenseNewsBreaks - Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Highlights Rare Earth Price Surge And Ranks Second On 2026 TSX Venture 50

Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ)

The QualityStocks Daily Newsletter would like to spotlight Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ).

Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include paid advertising.

• The Department of the Interior’s decision to open 2.1 million acres in Alaska’s Dalton Corridor clears a path for expanded mining access tied to the Ambler Road.
• Trilogy Metals holds a 50% interest in Ambler Metals, which owns 100% of the Upper Kobuk Mineral Projects spanning 190,929 hectares in the Ambler Mining District.
• The Arctic deposit hosts 46.7 million tonnes of probable mineral reserves grading 2.11% copper, alongside zinc, lead, gold and silver credits, positioning it among the highest-grade copper projects globally.

The United States’ push to secure domestic supplies of critical minerals has moved from policy discussion to actionable infrastructure decisions. Copper, zinc, silver and cobalt are essential inputs for power grid expansion, data centers, advanced manufacturing and defense systems. As federal agencies reopen access to strategic corridors in Alaska, the Ambler Mining District is re-emerging as one of the most consequential undeveloped mineral belts in North America.

In February 2026, the US Department of the Interior announced the revocation of two long-standing public land withdrawals in Alaska’s Dalton Utility Corridor, opening approximately 2.1 million acres to mining entry. The action was tied to Executive Orders aimed at strengthening domestic energy and mineral production. Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) holds a 50% interest in Ambler Metals LLC – a joint venture with South32 Limited – that owns 100% of the Upper Kobuk Mineral Projects in northwestern Alaska. The land package spans approximately 190,929 hectares, or 471,796 acres, across a largely underexplored volcanogenic massive sulphide belt.

Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) is a North American mineral exploration and development company focused on advancing high-grade copper and critical mineral assets in Alaska. The company operates through Ambler Metals LLC, a 50/50 joint venture with South32 Ltd., and is progressing one of the world’s most prospective undeveloped polymetallic districts.

Trilogy is uniquely positioned with exposure to copper, zinc, lead, cobalt, silver, and gold—commodities vital to global electrification and energy transition. Its vision is to responsibly develop the Ambler Mining District into a premier domestic source of critical minerals while delivering long-term value to shareholders and local communities.

The company is guided by values of trust, respect, integrity, and partnership, and works closely with Alaska Native stakeholders to advance its strategy in a sustainable and inclusive manner.

Projects

Arctic Project

The Arctic project is Trilogy’s flagship asset and one of the highest-grade known copper deposits in the world, with an average grade of approximately 5% copper equivalent. Located roughly 470 kilometers northwest of Fairbanks, Alaska, Arctic is a volcanogenic massive sulphide (VMS) deposit hosting copper, zinc, lead, gold, and silver. The project is at the feasibility stage and is currently undergoing permitting activities.

According to the 2023 Feasibility Study, Arctic will support a 10,000 tonne-per-day open-pit mining operation over a 13-year mine life. Based on long-term metal prices of $3.65/lb copper, $1.15/lb zinc, $1.00/lb lead, $1,650/oz gold, and $21.00/oz silver, the project demonstrates a pre-tax NPV8% of $1.5 billion and an IRR of 25.8%. After-tax, the NPV8% is $1.1 billion with a 22.8% IRR. At April 2025 spot metal prices, the after-tax NPV8% increases to $1.9 billion with a 31.1% IRR.

The project’s metallurgy supports high recoveries: 92.1% for copper, 88.5% for zinc, and 61.3% for lead. Life-of-mine payable production is projected to total 1.9 billion pounds of copper, 2.2 billion pounds of zinc, 335 million pounds of lead, 423,000 ounces of gold, and 36 million ounces of silver. Cash costs are expected to average $0.72 per pound of payable copper, with all-in costs estimated at $1.61 per pound.

Bornite Project

Located approximately 25 kilometers southwest of Arctic, the Bornite project is a large-scale carbonate replacement copper deposit with significant upside. According to the 2025 Preliminary Economic Assessment (PEA), Bornite is expected to support a 6,000 tonne-per-day underground operation over a 17-year mine life, using re-purposed infrastructure from the Arctic Project.

Bornite contains an estimated 6.5 billion pounds of inferred copper. The PEA outlines pre-tax NPV8% of $552.1 million and IRR of 23.6%, with an after-tax NPV8% of $393.9 million and IRR of 20.0%, based on a copper price of $4.20/lb. Total payable copper production over the life of mine is projected at 1.9 billion pounds.

Bornite’s mineralization occurs in stacked, stratabound zones rich in chalcopyrite, bornite, and chalcocite. A subset of the South Reef zone offers high-grade underground mining potential, further enhancing Bornite’s future optionality.

Exploration Pipeline

The Upper Kobuk Mineral Projects span 471,796 acres and include more than 30 additional mineralized prospects beyond Arctic and Bornite. These lie along two geologically distinct and highly mineralized belts: the Ambler Schist Belt and the Bornite Carbonate Sequence.

The Ambler Schist Belt features multiple VMS-style prospects along its 100-kilometer strike length, including Sunshine, Snow, Nora, Shungnak, and BT. Neighboring deposits like Smucker (Teck) and Sun (Valhalla Metals) affirm the district’s regional potential. Ten of Trilogy’s VMS prospects have been drill tested with encouraging results.

Meanwhile, the Bornite Carbonate Sequence extends 16 kilometers along the Cosmos Hills and hosts additional targets such as Pardner Hill and Aurora Mountain. These zones show strong signs of copper and cobalt mineralization and were partially tested during the Kennecott era, suggesting significant room for expansion.

Together, these assets form the foundation of a multi-decade development and discovery platform in one of the most prospective undeveloped mining districts in North America.

Market Opportunity

Trilogy Metals is poised to benefit from long-term structural demand for copper and other critical minerals essential to electrification, energy infrastructure, and clean technologies. Copper, in particular, is expected to see major supply shortfalls due to underinvestment and accelerating demand from power grids, EVs, and data centers.

According to a Grand View Research report, the global copper market is projected to grow from $241.88 billion in 2024 to $339.95 billion by 2030, at a CAGR of 6.5%, driven by the energy transition and rising infrastructure investments.

Trilogy’s Arctic and Bornite projects are strategically located in Alaska, a top-tier mining jurisdiction with strong permitting frameworks and growing federal and state-level support, including recent executive orders streamlining approvals for the Ambler Access Project. The company also maintains a $50 million shelf prospectus and an active $25 million ATM equity program to fund future development.

Leadership Team

Tony Giardini, President and Chief Executive Officer, leads Trilogy Metals with extensive executive experience in the mining industry. He previously served as President of Ivanhoe Mines Ltd., and as Executive Vice President and Chief Financial Officer at Kinross Gold Corporation. Earlier in his career, he held senior roles at Placer Dome Inc. and KPMG. Mr. Giardini is both a Chartered Professional Accountant and a Certified Public Accountant.

Elaine M. Sanders, Chief Financial Officer and Corporate Secretary, brings over 25 years of financial and accounting experience to Trilogy. She is responsible for the company’s financial reporting, compliance, and governance functions. Ms. Sanders has overseen multiple financings and exchange listings throughout her career. She holds a Bachelor of Commerce from the University of Alberta and is both a Chartered Professional Accountant and Certified Public Accountant.

Richard Gosse, Vice President, Exploration, is a veteran geologist with 35 years of global exploration experience. He previously led exploration initiatives at Dundee Precious Metals and Ivanhoe Mines Ltd., where he oversaw the discovery efforts at the renowned Oyu Tolgoi copper-gold project in Mongolia. Mr. Gosse holds a B.Sc. in Geology from Queen’s University and an M.Sc. in Mineral Exploration from Imperial College London.

Trilogy Metals Inc. (NYSE American: TMQ), closed Tuesday's trading session at $4.11, up 2.4938%, on 2,613,815 volume. The average volume for the last 3 months is 4,584,701 and the stock's 52-week low/high is $1.125/$11.29.

Recent News

• Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) - Unlocking Alaska's Critical Corridor: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Is Well Positioned in America's Future Mineral Supply Chain
• MiningNewsBreaks - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Highlights $35M Program to Advance Alaska's Upper Kobuk Mineral Projects
• Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Year-End Report Shows Alignment with Domestic Resource Priorities, Strong Strategic Positioning

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

South Korean scientists have published the results of a study that provides vital insights indicating that brain cancer develops much earlier than the time when tumors become visible. Their findings could alter how brain cancer treatment is approached, especially efforts geared at limiting the possibility of its recurrence. The study focused on IDH-mutant glioma, a type of brain cancer that is most common among brain cancer patients who haven’t reached the age of 50. This cancer is difficult to treat due to its high likelihood of regrowth after a patient has undergone therapy. The study also found that different subtypes of brain cancer have different origins. Doctor Jung W. Park, the first author of the study, explains that understanding where a particular tumor type originates can provide insights into how best to approach treatment so that the problem is addressed from its source rather than focusing on just where it is manifesting. Understanding the origin also makes it easier to develop techniques and tools for early diagnosis so that timely intervention increases chances of successful treatment while also lowering costs and preserving as much of the brain as possible during surgical procedures to remove tumor masses. The fight against primary brain cancers is attaining many successes on the research front, and it is just a matter of time before entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) focused on developing therapies for brain cancers commercialize novel treatments that change the paradigm of cancer care.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $3.35, up 10.9272%, on 117,855 volume. The average volume for the last 3 months is 24,540 and the stock's 52-week low/high is $2.7601/$55.2.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - New Research Challenges Current Thinking on How Brain Cancer Develops
• New Treatment Dramatically Improves Survival for Patients with Deadly Brain Tumors
• New Study Unveils Promising Way to Conduct Brain Surgery Against Cancer

Beeline Holdings Inc. (NASDAQ: BLNE)

The QualityStocks Daily Newsletter would like to spotlight Beeline Holdings Inc. (NASDAQ: BLNE).

• Beeline Holdings will host a stakeholder call on March 30 to discuss Q4 2025 financial results and operational updates.
• The company reported quarterly double-digit revenue growth in 2025 and ended the year with over $50 million in Balance Sheet  equity and no corporate debt.
• Beeline is scaling an AI-driven mortgage platform designed to shorten closing times and lower origination costs, and is expanding core mortgage, title, and home equity offerings heading into 2026.
• The company is positioning its products for millennials, gig-economy workers, and real estate investors, and recently introduced a blockchain-enabled home equity product, building SaaS revenue channels.

Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform redefining the path to homeownership, announced that it will host a stakeholder update call on March 30, 2026, to review its fourth-quarter 2025 financial results and outline upcoming initiatives, as the digital mortgage platform looks to build on a year of rapid growth. The call will be led by Chief Executive Officer Nick Liuzza and Chief Financial Officer Chris Moe and is scheduled for 5 p.m. ET. ( https://ibn.fm/0KGwI ).

Beeline Holdings Inc. (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive user experiences to simplify home financing. Through wholly owned subsidiary Beeline Loans Inc., the company delivers fast and flexible loan solutions for both primary homebuyers and real estate investors. Beeline has built an end-to-end digital lending ecosystem designed to eliminate friction, reduce costs, and dramatically shorten closing timelines.

Since completing its October 2024 merger with Eastside Distilling, Beeline has solidified its position as a next generation fintech mortgage originator. Its core vision centers on digitizing the mortgage journey with tools like AI chatbot Bob, proprietary production engine Hive, and an expanding SaaS product suite. These innovations enable Beeline to close loans in just 14–21 days—less than half the industry average—while achieving a Net Promoter Score above 80, more than four times higher than the sector benchmark.

Beeline’s mission is to make home loans effortless by giving users instant access to rate quotes, approvals, and document uploads—all online, 24/7. Having surpassed $1 billion in cumulative loan originations and achieved 38% year-over-year growth, Beeline is scaling its platform across the U.S. mortgage and real estate investing landscape.

The company is headquartered in Providence, Rhode Island.

Products

Beeline operates a fully digital, AI-enabled loan origination and title ecosystem. Key features include:

• Bob 2.0 – The industry’s first AI mortgage agent, available 24/7/365 to quote rates and pre-approve borrowers; Bob has delivered 6x lead conversion and 8x full application volume compared to traditional loan officers.
• Hive – A task-based processing engine that replaces manual workflows with scalable automation, cutting loan closing times to as little as 14 days.
• BlinkQC – Beeline’s proprietary AI quality control platform that replaces costly third-party reviews.
• Beeline Title – A fully diversified title services unit supporting digital collateral transfer, remote closings, and investor-focused solutions.
• MagicBlocks – A customizable AI sales agent platform developed by Beeline and spun out into its own entity; Beeline retains equity and licensing rights, positioning it to benefit from future growth and deployment of the technology.

The company also provides Debt Service Coverage Ratio (DSCR), bank statement, and conventional mortgage products tailored to investors, including short-term rental operators. Strategic partnerships with Rabbu and Red Awning streamline property analysis, financing, and management within a single ecosystem.

Market Opportunity

The U.S. mortgage market is poised for growth in 2025, with total mortgage origination volume expected to increase by 28% to $2.3 trillion, up from $1.79 trillion in 2024. This projection includes a 13% rise in purchase originations to $1.46 trillion.

Within this expanding market, investor lending, particularly through DSCR loans, represents a rapidly growing segment. DSCR loans, which are underwritten based on the income generated by the property rather than the borrower’s personal income, are ideal for real estate investors, particularly those purchasing long-term or short-term rental properties. Beeline has strategically positioned itself in this niche, with over one-third of its volume derived from DSCR products. Through its affiliate referral network and integrations with platforms like Rabbu, the company is actively expanding its market reach in this high-margin category.

Non-agency mortgage issuance, which includes DSCR loans, is projected to reach $160 billion in 2025, a 16% increase from 2024.

Leadership Team

Nick Liuzza, Chief Executive Officer, co-founded Beeline Mortgage LLC in 2019 after selling Linear Title & Closing and Linear Settlement Services to Real Matters. He also previously built New Age Nurses into a national staffing firm. He currently serves as EVP of Real Matters (TSX: REAL).

Jess Kennedy, Chief Operating Officer, is a co-founder of Beeline with 15 years of legal and real estate experience. She previously served as General Counsel and Chief Compliance Officer at Beeline and held roles at Solidifi, LeClairRyan, and Edwards Wildman Palmer LLP, handling complex real estate finance and title transactions.

Chris Moe, Chief Financial Officer, joined Beeline in 2023 with over 40 years of finance and investment banking experience. He has held senior roles at Red Cat Holdings (NASDAQ: RCAT), IRIS Therapeutic Devices, and Yates Electrospace Corporation, bringing deep public company and defense sector expertise.

Beeline Holdings Inc. (NASDAQ: BLNE), closed Tuesday's trading session at $2.98, up 1.3605%, on 990,224 volume. The average volume for the last 3 months is 708,278 and the stock's 52-week low/high is $0.6202/$6.85.

Recent News

• Beeline Holdings Inc. (NASDAQ: BLNE) - Beeline Holdings Inc. (NASDAQ: BLNE) Sets March 30 Call to Review Q4 Results, Including a $100M Run Rate by December 2027
• Beeline Holdings Inc. (NASDAQ: BLNE) AI-Driven Mortgage Platform Prioritizes Speed, Easy Access for Personal Home Buyers and Investors
• MissionIRNewsBreaks - Beeline Holdings Inc. (NASDAQ: BLNE) Featured by Streetwise Reports for Rapid Revenue Growth and Fintech Expansion

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine (“PIM”) designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the treatment of Behçet’s Disease. The designation represents the first step toward potential inclusion in the U.K.’s Early Access to Medicines Scheme, which allows patients with life-threatening or seriously debilitating conditions to access promising therapies earlier. The PIM designation was granted based on Phase 2 clinical data indicating that dusquetide may provide a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile for patients with this rare inflammatory disorder.

To view the full press release, visit https://ibn.fm/N8oN5

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Tuesday's trading session at $1.23, up 2.5%, on 344,085 volume. The average volume for the last 3 months is 148,999 and the stock's 52-week low/high is $1.02/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease
• Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
• BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF)

The QualityStocks Daily Newsletter would like to spotlight Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF).

This article has been disseminated on behalf of Lahontan Gold Corp. and may include paid advertising.

Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) announced the appointment of Antony Rowe and Miranda Werstiuk as independent directors to the company’s board of directors. In conjunction with the appointments, Josh Serfass and Max Pluss have stepped down from the board. The leadership update comes as the company advances its business strategy and progresses the Santa Fe Mine project toward gold and silver production, with management noting that the refreshed board brings experience in mine development and mining finance to help guide Lahontan through its transition from mine developer to mine builder.

To view the full press release, visit https://ibn.fm/1QEig

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) is a Canadian mine development and exploration company advancing a portfolio of gold and silver assets in Nevada’s Walker Lane, one of the world’s most productive and mining-friendly regions. Through its U.S. subsidiaries, the company controls four gold and silver properties in Nevada, three of which are 100%-owned and one controlled via a low-cost option to acquire full ownership. With a clear near-term path to production, Lahontan is focused on unlocking oxide gold and silver value from past-producing, infrastructure-rich projects.

The company’s mission is to responsibly develop and expand its oxide resources while minimizing capital intensity and maximizing economic returns. Leveraging a strong technical team with a track record of advancing projects and building mines, Lahontan is focused on growing gold and silver resources and hitting permitting milestones across multiple sites. Its strategy prioritizes scalability, efficiency, and timely value realization for shareholders.

By maintaining full project ownership and a capital-light development model, Lahontan Gold is positioned to rapidly transition from development to production.

The company is headquartered in Toronto, Ontario.

Projects

Santa Fe Mine

The 26.4 km² Santa Fe Mine is Lahontan’s flagship asset and core development priority. A past-producing open-pit, heap-leach gold and silver operation, Santa Fe historically yielded more than 359,000 ounces of gold and 702,000 ounces of silver between 1988 and 1995. The site benefits from established infrastructure—including power, water, and road access—and more than 79% of its known resources are unencumbered by royalties.

A 2024 NI 43-101 resource estimate outlines 1.54 million ounces of gold equivalent (AuEq) in the Indicated category and 0.41 million ounces Inferred, all pit-constrained. Oxide resources average among the highest grades in the state and are distributed across five known deposits. A 2025 Preliminary Economic Assessment (PEA) projects strong economic returns, including an after-tax NPV5% of $200 million, a 34.2% internal rate of return (IRR), and average annual production of approximately 50,000 ounces AuEq over an eight-year mine life.

Permitting is well underway for both the Exploration and Mine Plans of Operation, covering over 12 km² and more than 700 drill holes. The company is targeting construction permits in late 2026 and continues to pursue oxide resource expansion and metallurgical optimization, particularly within the Slab-Calvada corridor.

West Santa Fe

West Santa Fe lies just 13 kilometers from the flagship and is being explored as a potential satellite operation. The project is defined by a shallow, oxide-dominant gold-silver system with a conceptual target of 0.5 to 1.0 million ounces AuEq based on historic drilling and recent surface sampling, which returned up to 2.61 g/t Au and 899 g/t Ag (14.6 g/t AuEq). A 6,300-meter Phase One reverse circulation drill program is scheduled for 2025 to validate historical data and support a maiden resource estimate. Development is streamlined under a low-cost option agreement and a rapid permitting path via Notice of Intent.

Moho and Redlich

The Moho and Redlich projects provide additional longer-term upside within Lahontan’s portfolio. Moho features high-grade, oxidized epithermal veins with historic production at grades of 20–25 g/t Au and 300 g/t Ag. A 2019 core drill program confirmed the presence of high-grade mineralization at depth. Redlich, located along trend from the historic Candelaria silver mine, hosts disseminated Ag mineralization in epithermal veins and hydrothermal breccias but remains untested by drilling. While no near-term programs are currently disclosed, both assets represent future exploration optionality.

Market Opportunity

Lahontan Gold operates in Nevada, consistently ranked the top global mining jurisdiction by the Fraser Institute due to its transparent permitting process, legal stability, and established infrastructure. Nevada produces over 4.5 million ounces of gold annually, generating approximately $9 billion in value, and ranks fifth globally in total gold production.

According to the World Gold Council, total gold demand in Q1 2025 reached 1,206 tonnes, up 1% year-over-year, marking the strongest first quarter since 2016. Central banks added 244 tonnes to reserves, a slight slowdown from the prior quarter but well within the strong buying range observed over the past three years. Meanwhile, silver demand is supported by strong industrial usage in solar panels, electric vehicles, and semiconductors, with long-term deficits forecast in the physical silver market.

With macro-driven demand for gold, technology-driven silver consumption, and strong institutional buying across both metals, Lahontan is uniquely positioned to capitalize through its portfolio of oxide-focused projects in a top-tier jurisdiction—offering near-term production potential and longer-term resource expansion.

Leadership Team

Kimberly Ann, Founder, CEO, President & Executive Chair, is a veteran mining executive with a track record of founding and scaling junior resource companies. She has raised over $210M in financing and led the $340M buyout of Prodigy Gold. Her prior roles include CFO of PPX Mining and founder of Latin America Resource Group, which merged with Carube Copper to form C3 Metals.

Brian Maher, Founder and VP of Exploration, is an economic geologist with more than 45 years of experience. He previously led Prodigy Gold as CEO, where he helped develop the Magino gold project before its $341M acquisition. His career includes senior roles at ASARCO, Hochschild Mining, and PPX Mining, where he oversaw exploration and production in the Americas.

John McNeice, Chief Financial Officer, is a Chartered Professional Accountant with three decades of experience in public company reporting. He has served as CFO for seven public resource companies and played a key role in Ur-Energy Inc.’s TSX IPO and $150M in financings. He also serves as CFO for Gold79 Mines, C3 Metals, and Northern Graphite Corp.

Lahontan Gold Corp. (OTCQB: LGCXF), closed Tuesday's trading session at $0.3579, up 19.8593%, on 1,685,224 volume. The average volume for the last 3 months is 3,500,850 and the stock's 52-week low/high is $0.02295/$0.3854.

Recent News

• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) - MiningNewsBreaks - Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Appoints Two Independent Directors to Board
• MiningNewsBreaks - Lahontan Gold Corp. (TSXV: LG) (OTCQB: LGCXF) Mobilizes Reverse-Circulation Drill Rig at Santa Fe Mine
• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Announces Final Results from the 2025 Maiden Drilling Program at the West Santa Fe Project, Plans for Spring Drilling Campaign

Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF)

Disseminated on behalf of Nevada Organic Phosphate Inc., may include paid advertisements.

The QualityStocks Daily Newsletter would like to spotlight Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF).

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising.

Nevada Organic Phosphate (CSE: NOP; OTCQB: NOPFF) announced that its environmental consultants and exploration team have mobilized to the Murdock Mountain Property, marking the official start of the company’s 2026 field season. Following several weeks of weather delays, crews have begun environmental baseline work, access inspections and field preparations to support an upcoming drill program, with drilling expected to begin soon as ground conditions continue to stabilize. In addition to advancing the core project, the company will begin exploring three additional lease applications that host extensions of the main phosphate target zones, potentially expanding the project’s long-term growth opportunity.

To view the full press release, visit https://ibn.fm/AmmJY

Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) is a junior exploration company focused on exploring and advancing an organic sedimentary raw rock phosphate project in northeast Nevada. The company’s business model centers on developing a rare, direct-application phosphate product that aligns with the growing demand for organic agricultural inputs. Its vision is to support the rapidly expanding organic food industry with a clean, reactive, environmentally responsible nutrient source that avoids the contamination issues associated with chemically processed fertilizers.

NOP is advancing the Murdock Mountain Project through disciplined exploration, responsible environmental practices, and strategic planning that positions the company as a future supplier of organic phosphate to key agricultural markets. The company emphasizes transparency, environmental stewardship, and adherence to regulatory standards as it advances its drill program and project development.

By developing a unique phosphate resource in a mining-friendly U.S. jurisdiction with strong infrastructure access, NOP aims to establish itself as a significant participant in the organic fertilizer sector.

The company is headquartered in Vancouver, British Columbia.

The Murdock Mountain Phosphate Project

NOP’s flagship asset is the Murdock Mountain Phosphate Project in Elko County, Nevada, a nearly flat-lying sediment-hosted phosphate system traced historically over 6.6 kilometers and extended through additional applications to more than 30 kilometers. The project’s raw rock phosphate is characterized by high purity, absence of heavy metals, and suitability for direct application without processing, aided by francolite (the most reactive crystallite structure of all P₂O₅ minerals) and oolitic textures that provide optimal surface area for interaction with soil micro-organisms. The product’s purity places it within the rare 5% of global P₂O₅ material pure enough for direct field application.

The Murdock Mountain property spans four Bureau of Land Management (BLM) applications totaling 7,824 acres, with an Exploration Target Mineral Inventory (ETMI) of 10–46 million tonnes in the initial 1,813-acre area and an additional 200–220 million tonnes across three further applications. Historic geologic mapping and recent drilling identify the Upper Phosphatic Zone within the Meade Peak Member as the primary target, with an interval historically ranging from 3.4 to 7.6 meters thick within a 28–40-meter phosphatic sequence.

In 2025, NOP commenced a multi-hole drill program with unrestricted seasonal timing following regulatory updates. Drill holes MM25-1, MM25-2, MM25-3, MM25-4 and MM25-5 all intersected favorable Meade Peak phosphate-bearing stratigraphy precisely where predicted by geological modeling. These intersections ranged from 29.2 to 38 meters (96 to 125 feet), with drilling confirming the interpreted dip and continuity of the target zone. Ongoing step-out drilling continues along the phosphate trend, supported by geological mapping and XRF screening, with assays pending. The project benefits from proximity to Highway SR 30, the hamlet of Montello, and the Southern Pacific rail line, enabling a simple mining concept summarized by: “break it up, dig it up, grind it up, bag it up, and ship it out.”

Market Opportunity

NOP intends to supply organic, direct-application phosphate fertilizer to the rapidly expanding organic food sector in North America. The company cites a $35 billion organic food market, supported by data from the U.S. Department of Agriculture’s Economic Research Service, which estimated an 8.7% annual growth rate between 2021 and 2027.

The shift toward organic and regenerative agriculture is driving demand for reactive, non-acidulated phosphate sources, and NOP notes that American farming practices are increasingly moving toward direct-application phosphate rather than soluble chemical fertilizers. With only 5% of global P₂O₅ pure enough for direct application, the company is targeting a rare, high-value segment of the fertilizer market that does not require competition with conventional chemical fertilizer producers.

Leadership Team

Robin Dow, Chairman & CEO, brings extensive experience as a public venture capital entrepreneur, following prior roles as a retail and institutional broker and researcher at Burns Fry. He has created more than 30 private and public companies across multiple sectors, raised close to $200 million, and built resource operations spanning four continents, 10 countries, four U.S. States, four Canadian provinces, and three Canadian territories.

Eric Szustak, Director, offers over 39 years of financial services, accounting, business development, and marketing experience, supported by senior roles at firms including Midland Walwyn, Merrill Lynch, and BMO Nesbitt Burns. He is the former President and current Chairman of Quinsam Capital Corporation and holds multiple directorships in publicly listed companies.

Garry K. Smith, Director, contributes more than 40 years of exploration management for companies such as Kerr Addison, Teck, Rio Tinto, and Lac Minerals. As a Qualified Person, he specializes in project generation, 43-101 reporting, resource evaluation, geological modeling, and metal ion soil geochemistry, with a strong focus on ethical and environmentally responsible exploration practices.

Paul W. Pitman, P.Geo., Director, is a field hardened veteran with extensive experience in all areas of geological exploration for a number of metals and materials. He has over 55 years’ experience as an exploration geologist. Since 1983, he has acted as a geological consultant to over 70 clients, providing a full range of services (geological, corporate, and administrative). He has served as a Director or Officer (VP or President) of several junior resource companies, including Boreal Agrominerals, a producer off organic fertilizers from igneous rock in Northern Ontario. He is semi-retired but directs his geological expertise as an advisor to several fertilizer companies.

Nevada Organic Phosphate Inc. (OTCQB: NOPFF), closed Tuesday's trading session at $0.101, up 9.7826%, on 269,662 volume. The average volume for the last 3 months is 698,360 and the stock's 52-week low/high is $0.0334/$0.3212.

Recent News

• Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) - RockBreaks - Nevada Organic Phosphate Inc. (CSE: NOP; OTCQB: NOPFF) Mobilizes Teams to Murdock Mountain for 2026 Field Season
• RockBreaks - Nevada Organic Phosphate Inc. (CSE: NOP; OTCQB: NOPFF) Highlights U.S. $1 Billion Sustainable Farming Investment as Potential Tailwind for Organic Phosphate
• MiningNewsBreaks - Nevada Organic Phosphate Inc. (CSE: NOP; OTCQB: NOPFF) Enters Consultant Agreements for Murdock Property Development and Media Relations

Renewal Fuels Inc. (OTC: RNWF)

The QualityStocks Daily Newsletter would like to spotlight Renewal Fuels Inc. (OTC: RNWF).

Renewal Fuels (OTC: RNWF) ,  doing business as American Fusion Inc., was featured in the latest episode of The Stock2Me Podcast released by IBN, highlighting Kepler Fusion Technologies, a wholly owned subsidiary developing the Texatron(TM) aneutronic fusion platform. During the episode, Kepler Fusion CEO Brent Nelson discussed the company’s progress toward deploying a fully operational 100-megawatt fusion reactor, including a 5-megawatt pre-production model currently under development, and outlined its power-as-a-service strategy targeting data centers and industrial customers. Nelson also detailed the company’s economic model and scaling plans, noting potential pricing of approximately 6.25 cents per kilowatt-hour and a long-term goal of delivering about one gigawatt of power by 2028 as the company works to commercialize fusion-based energy solutions.

To view the full press release, visit https://ibn.fm/hLVfa

Renewal Fuels Inc. (OTC: RNWF) (d/b/a American Fusion) is an advanced energy platform company focused on building a scalable, infrastructure-grade fusion energy business through its wholly owned subsidiary, Kepler Fusion Technologies. Following a completed reverse merger with Kepler, the company has repositioned itself around the development and long-term commercialization of deployable fusion power systems designed for real-world industrial and infrastructure use rather than experimental research programs.

The company’s strategy centers on pairing proprietary fusion technology with disciplined governance, intellectual property development, and a public-company operating framework intended to support long-duration value creation. Management has emphasized transparency, regulatory readiness, and institutional credibility as foundational elements alongside continued technical progress.

Renewal Fuels is in the process of transitioning its public identity to American Fusion to reflect its strategic focus on advanced fusion energy infrastructure and commercialization.

The company is based in Southlake, Texas.

Kepler Texatron™

Through wholly owned subsidiary, Kepler Fusion Technologies, the company is developing the Texatron™ aneutronic fusion platform, a compact, pulsed fusion system engineered specifically for commercial and infrastructure-grade deployment. Unlike steady-state fusion concepts that prioritize laboratory demonstration, the Texatron™ operates in controlled cycles designed to support modular scalability, redundancy, and distributed installation across multiple end markets.

The platform is optimized around a Deuterium–Helium-3 fuel pathway that enables direct electrical energy conversion, reducing reliance on traditional steam cycles and minimizing neutron-related material degradation. This design supports a smaller physical footprint and greater flexibility for deployment in grid-constrained or mission-critical environments such as data centers, industrial facilities, defense installations, and remote locations.

Kepler’s commercialization model is structured around a Power-as-a-Service approach under which the company intends to retain ownership of its fusion units and sell electricity to customers under long-term contractual arrangements. This infrastructure-oriented model is designed to align system deployment with predictable, recurring revenue while allowing for fleet-based scaling over time. The platform is supported by a broad and expanding intellectual property estate encompassing reactor architecture, energy conversion systems, control technologies, manufacturing processes, and deployment methodologies.

Market Opportunity

U.S. electricity demand has re-entered a period of sustained growth following nearly two decades of relative stagnation, according to data from the U.S. Energy Information Administration. After years in which efficiency gains and structural economic shifts largely offset population and economic growth, electricity consumption has increased meaningfully since 2020 and is forecast to continue rising through at least the middle of the decade.

Recent and projected growth is being driven primarily by the commercial and industrial sectors, with data centers, advanced manufacturing, and other power-intensive operations accounting for a disproportionate share of incremental demand. These segments tend to require continuous, non-intermittent electricity supply, placing increased pressure on existing generation and transmission infrastructure.

This shift underscores a growing need for reliable baseload power sources that can be deployed without extensive new transmission build-out and that align with emissions-reduction objectives. Fusion-based energy systems designed for distributed, infrastructure-grade deployment represent a potential long-term solution for meeting rising demand in environments where reliability, resilience, and scalability are critical.

Leadership Team

Richard Hawkins, Chairman and Chief Executive Officer, has overseen the company’s strategic reset, corporate restructuring, and transition toward an advanced fusion energy platform, with responsibility for governance, capital markets strategy, and long-term corporate development.

Brent Nelson, Chief Executive Officer of Kepler Fusion Technologies, brings extensive experience in energy systems and commercialization strategy and leads the development, validation, and deployment roadmap for the Texatron™ fusion platform, as well as Kepler’s intellectual property and operating model.

Renewal Fuels Inc. (OTC: RNWF), closed Tuesday's trading session at $0.05, up 32.626%, on 51,039,512 volume. The average volume for the last 3 months is 16,336,980 and the stock's 52-week low/high is $0.000001/$0.0518.

Recent News

• Renewal Fuels Inc. (OTC: RNWF) - InvestorNewsBreaks - Renewal Fuels, Inc. (OTC: RNWF) Subsidiary Kepler Fusion Featured on Latest Stock2Me Podcast Episode
• GreenEnergyBreaks - Renewal Fuels, Inc. (OTC: RNWF) Issues Commentary on Energy Security Amid Middle East Escalation, Highlights Texatron(TM) Fusion Progress
• GreenEnergyBreaks - Renewal Fuels, Inc. (OTC: RNWF) Closes Kepler Fusion Transaction, Advances SEC Reporting and American Fusion Transition

Wearable Devices Ltd. (NASDAQ: WLDS)

The QualityStocks Daily Newsletter would like to spotlight Wearable Devices Ltd. (NASDAQ: WLDS).

Wearable Devices (NASDAQ: WLDS) , a technology growth company specializing in artificial intelligence-powered touchless sensing wearables, announced it will implement a one-for-three reverse split of its ordinary shares and tradable warrants, effective when trading begins on a split-adjusted basis on March 11, 2026. The action is intended to increase the company’s per-share trading price to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. Following the reverse split, the number of issued and outstanding ordinary shares will be reduced from 10,593,227 to approximately 3,531,076, while publicly held warrants will decrease from 98,589 to about 32,863, with trading to continue under the existing ticker symbols “WLDS” and “WLDSW.” The move was approved by shareholders at a Feb. 19, 2026 special meeting, and the company expects the reverse split to maintain proportional ownership among shareholders, subject to rounding adjustments for fractional shares.

To view the full press release, visit https://ibn.fm/wLOiS

Wearable Devices Ltd. (NASDAQ: WLDS) is a growth-stage technology company pioneering the next generation of human-computer interaction through AI-powered neural input wearables. Mudra, its proprietary wrist-worn technology, enables touchless, gesture-based control of digital devices, offering users a seamless, intuitive interface through subtle finger and hand movements. Since introducing its technology to the market in 2014, the company has pursued both business-to-business (B2B) and business-to-consumer (B2C) strategies through a dual-channel model.

The company believes the future of technology should begin with the human. Wearable Devices envisions decoding the human body to enable context-aware AI-powered technology that listens, learns, and adapts – to us.

The company envisions a future where human intent becomes the language of technology. Through non-invasive neural sensing and adaptive algorithms, the company enables more natural, personalized, and intuitive interactions with computers.

The company is headquartered in Yokneam Illit, Israel.

Products

Neural control has entered the market: commercially available since 2023 with the Mudra Band and already used by thousands of users worldwide. With its product line, including Mudra Band and Mudra Link, the company has introduced the world’s first wrist-worn neural interfaces, enabling intuitive, touchless control through natural micro-gestures: subtle finger movements and wrist flicks. Whether streaming media, controlling smart devices, or interacting with AR glasses, Mudra brings neural input into everyday life.

This early adoption isn’t just validation — it’s acceleration. With real users engaging in real environments, the company is learning fast, improving faster, and shaping a product that grows more refined with every interaction.

Mudra Band

Mudra Band is the company’s flagship B2C product, designed as a sleek, aftermarket accessory for the Apple Watch. It uses patented sEMG sensors to detect neural signals from the wrist and translates them into real-time digital commands. This allows users to control and streamline interactions between the iPhone, iPad, MacBook, and Apple TV using familiar micro-gestures like taps, pinches, or swipes — all without touching a screen.

The device features a high-resolution analog front end, IMU integration, adaptive machine learning, and ergonomic form factors for all-day comfort. Users can toggle between multiple Apple devices using the Mudra Band’s dedicated Apple Watch face, enabling a fully connected, touchless experience. The Mudra Band is optimized for low-latency, high-accuracy interactions and supports a wide range of digital applications. The Mudra Band received a CES 2021 Innovation Award.

Mudra Link

Mudra Link expands the company’s reach beyond the Apple ecosystem, offering compatibility with Android, Windows, and AR/XR platforms. The product includes the innovative Gesture Mapper feature, allowing users to assign personalized commands to gestures such as tap, pinch, flick, or twist. This functionality replaces or augments traditional input methods, supporting media controls, pointer input, and full directional mapping. A key feature of Mudra Link is its dual-mode input system (mouse mode or D-pad mode), empowering users to personalize control schemes across devices, operating systems, and user interfaces.

Mudra Link is recognized for its ergonomic design, lightweight build, and plug-and-play ease of use. It supports native integration with AR glasses from leading manufacturers and received a CES 2025 Innovation Award.

Mudra DevKit and Integration

In parallel with its consumer devices, Wearable Devices offers a Mudra Developer Kit (MDK) and integration program for enterprise and OEM partners. The MDK includes full-stack tools (hardware bands, SDK, APIs, and sample code) that allow developers and original equipment manufacturers to embed Mudra’s neural sensing capabilities into their own products and applications. For example, an AR headset maker can integrate Mudra’s sensors to enable native hand-gesture input, or a software developer can use Mudra’s API to track user gestures for novel interactions.

The MDK supports both Android and iOS and even provides real-time neural raw signal monitoring for research and prototyping. This B2B offering not only expands Mudra technology into new environments such as industrial automation, robotics, and gaming peripherals, but also fosters a broader ecosystem of Mudra-powered solutions. By lowering the barrier for others to adopt its AI gesture recognition engine, Wearable Devices accelerates innovation and garners strategic relationships.

The MDK and related licensing offerings illustrate Wearable Devices’ push-pull strategy: selling consumer products today, while seeding ‘Mudra inside’ into other companies’ devices tomorrow.

Market Opportunity & Strategy

Wearable Devices operates at the intersection of neural interfaces, wearable computing, and the rapidly expanding AR/XR sector. According to MarketsandMarkets, the global AR and VR market is projected to grow from $22.12 billion in 2024 to $96.32 billion by 2029, at a CAGR of 34.2%. The rising demand for natural, hands-free input methods positions neural wearables like Mudra as foundational components in spatial computing and smart environments.

Additionally, the health monitoring wearables market is gaining traction as neural biosignals become a promising data source. The company’s LMM (Large Motor Unit Action Potential Model) platform is being explored for predictive health monitoring, cognitive state tracking, and performance analytics. Government-level support, such as advocacy from the U.S. Secretary of Health and Human Services, further validates the sector’s momentum.

Combined with patent-protected technology and strategic alliances with companies like Qualcomm, TCL-RayNeo™, and Media Exceed, Wearable Devices is well-positioned to capture value across consumer, enterprise, and healthcare verticals.

The company’s phased market strategy anticipates this:

• Phase 1 – Enthusiast Consumer Adoption: Introduce Mudra Band as an add-on for Apple Watch (tapping into a passionate user base of early adopters and tech enthusiasts). Achieve proof-of-concept and get market feedback. This phase built brand credibility and seeded a community of users.
• Phase 2 – Expand Platform & Ecosystem: Launch Mudra Link for all users and open the Mudra SDK to developers and B2B partners. Focus on the XR/AR market and tech-savvy consumers, while enabling enterprise use-cases through the Developer Kit and strategic partnerships. The company is actively showcasing its tech to industry leaders and integrating with their platforms.
• Phase 3 – Leverage Data & Enter New Verticals: With a growing user base, Wearable Devices is collecting an invaluable dataset of neural signals and usage patterns. If data is the new oil for AI, neural signals will power the next computing revolution — enabling machines to understand human intent in real time. This fuels its Large Motor-Unit Action Potential Model (LMM) – a bio-signal intelligence platform that continuously learns from neural data to improve accuracy and enable new applications. One major new vertical is digital health and wellness: Wearable Devices is adapting its tech to track physiological and cognitive indicators from the wrist. Because the Mudra sensors capture muscle activation signals, they can potentially detect patterns related to stress, fatigue, focus, and even early signs of health conditions before traditional symptoms appear, and Wearable Devices recently announced it is expanding LMM into predictive health monitoring and cognitive analytics. This means the company could offer solutions for workplace productivity (measuring alertness), athletic training (muscle fatigue analytics), or preventive healthcare (flagging neuromuscular irregularities) – vastly broadening its addressable market. Through monitor applications, the vision is to go from controlling devices to also understanding the user, providing actionable bio-insights. The LMM platform’s AI continuously adapts to each individual’s neural profile, enabling truly personalized and proactive applications.
• Phase 4 – Ubiquitous Adoption via B2B Integration: Finally, Wearable Devices plans to drive mass adoption by aligning with major consumer tech players. By making its Mudra Data Platform available to enterprises, OEMs, and app developers, the company positions itself as the backbone for neural interaction services. By “laying the groundwork for the next neural frontier”, Wearable Devices is ensuring that when the tech giants move to adopt neural input, its platform is the mature, data-rich standard ready to be deployed.

Through these phased efforts, Wearable Devices balances B2C and B2B paths. It generates near-term revenues and user feedback via direct consumer product sales, while simultaneously developing long-term enterprise relationships and intellectual property value. This dual model not only diversifies revenue streams but also reinforces the technology’s credibility: consumer adoption demonstrates demand and usability, which in turn attracts enterprise interest, creating a virtuous cycle.

Leadership Team

Asher Dahan, Chief Executive Officer, co-founded Wearable Devices Ltd. in 2014 and has served as CEO and director since 2016. He is a seasoned executive with proven expertise in strategic planning, project execution, and business leadership. Asher oversees the company’s operations and resources, guiding major corporate decisions and long-term vision. Prior to founding Wearable Devices, he held engineering and leadership roles at Intel Haifa, specializing in high-speed interface validation. He holds a BSc in Electrical Engineering from Ort Braude College.

Guy Wagner, Chief Scientific Officer and President, co-founded Wearable Devices Ltd. in 2014 and has served on its board since inception. As CSO and President, Guy leads the company’s technological innovation and scientific direction. He is the main inventor behind the company’s core technology and brings multidisciplinary expertise in hardware design, biomedical signal processing, embedded programming, and sensor systems. He previously worked at Intel as a hardware engineer and holds a BSc in Electrical Engineering from Ort Braude College.

Leeor Langer, co-founder and CTO since 2016, is a leading expert in algorithms, machine learning, and signal and image processing. He has held senior R&D roles in the medical imaging and digital security sectors, including at Intel, and brings deep academic and industry experience. Leeor has authored several scientific papers and holds a BSc from the Technion and an MSc in Applied Mathematics from Tel Aviv University, graduating cum laude.

Wearable Devices Ltd. (NASDAQ: WLDS), closed Tuesday's trading session at $0.68, off by 6.8493%, on 426,684 volume. The average volume for the last 3 months is 54,773 and the stock's 52-week low/high is $0.6111/$34.1997.

Recent News

• Wearable Devices Ltd. (NASDAQ: WLDS) - TechMediaBreaks - Wearable Devices Ltd. (NASDAQ: WLDS) to Debut Mudra Experience Studio at MWC Barcelona 2026
• TechMediaBreaks - Wearable Devices Ltd. (NASDAQ: WLDS) Launches ai6 Labs Neural AI Ecosystem to Bridge Human Intent and Digital Reality
• AINewsBreaks - Wearable Devices Ltd. (NASDAQ: WLDS) Featured in AINewsWire Editorial on Next Wave of AI Investment

Numa Numa Resources Inc.

The QualityStocks Daily Newsletter would like to spotlight Numa Numa Resources Inc.

As 2025 came to a close, the Finance Minister of the Democratic Republic of Congo announced that the country had recommenced its exports of cobalt. This comes after a 10-month hiatus that was introduced early last year. While the initial plan had been to ban exports for only 4 months in an effort to control declining prices caused by oversupply and stabilize the market, the suspension was extended. At the time, the Strategic Mineral Substances Market Regulation and Control Authority explained that the decision to prolong the temporary suspension was made, because stock levels in the market remained high. Fwamba noted that the strategy imposed was successful, with cobalt prices rising to about $55,000 per ton from $22,000. In the DRC, cobalt is primarily extracted from mines situated in Katanga, a province located in the southeastern region. This area, which is considered crucial to the strategic and economic interests of Kinshasa, has so far remained largely unaffected by the intense violence affecting the North and South Kivu provinces, much of which are currently under the control of M23 rebels. The cobalt export curbs instituted by the DR Congo highlight how vulnerable the global market can be when supply is concentrated in one country. The world currently faces a similar vulnerability due to China’s control of the extraction and refining of many critical minerals. As exploration companies like Numa Numa Resources Inc. make headway in identifying viable deposits of many mineral resources, the dominance of one industry player in key supplies could eventually be broken.

Numa Numa Resources Inc. is a mining and infrastructure development company focused on unlocking transformational opportunities in the Autonomous Region of Bougainville, where the company is headquartered and where its management has lived and worked for 10 years.

Bougainville, a resource-rich archipelago in the South Pacific, is perhaps best known as the home of the Panguna Mine. Developed by Rio Tinto, the Panguna Mine was the largest open cut copper and gold mine in the world when it operated from 1972 to 1989 before being shuttered due to a civil war, called “the Crisis,” between Bougainville and its parent government Papua New Guinea. In 2001, the Bougainville Peace Agreement ended the war and awarded Bougainville limited autonomy, including its own constitution, by which ownership of the mine reverted to its customary landowners. A majority of the Panguna Mine’s copper, gold, and silver ore resources remain within its walls, making the fully explored and developed Panguna Mine one of the largest ore bodies in the world, today worth approximately $100 billion. Most geologists who have studied Bougainville believe that other nearby locations such as Mainoki and Karato are highly prospective and may contain ore deposits similar in size and scale to those of the Panguna Mine.

Numa Numa’s fundamental strength is the relationships it has developed over the years with the landowners in the Panguna, Mainoki, and Karato resource areas.

Pursuant to newly executed written agreements, Numa Numa has formed and now owns a stake in three new corporate entities that will own and develop, with the Panguna, Mainoki, and Karato landowners, their respective resources as partners pursuant to the laws and regulations of Bougainville. One entity has been established for Panguna, one for Mainoki, and one for Karato. Each entity is co-owned with the landowners of those respective areas. Each owns all the landowners’ resource rights to that area, and each entity is to be managed by a joint company/landowner team led by Numa Numa. Due to Bougainville’s constitution and law, each of these entities therefore effectively controls the monetization of the resources in its area. In Bougainville, the landowners—not the government—own the resources. With the Panguna, Mainoki, and Karato landowners as its contractual partners, Numa Numa now expects to prosper significantly in its mining endeavors in Bougainville.

Numa Numa has a contractual agreement to develop the Panguna Mine executed both with the Panguna Mine Landowner Clan Chiefs—the governmentally accepted owners of the Panguna Mine—and the government of Bougainville and President Ishmael Toroama, along with its rights to the exploration licenses regarding Mainoki and Karato for which it has applied and is awaiting approval. The company will be pursuing all such rights through those corporate entities. Numa Numa, together with its landowner partners, fully expect that these entities will ultimately be issued licenses and approvals by the government to legally pursue mining activities in their respective areas. Together with the Panguna, Mainoki, and Karato landowners, Numa Numa then intends to partner with mining companies who are now being invited to explore, fully develop, and ultimately construct and operate these prime Bougainville mining opportunities.

These new assets distinguish Numa Numa from any other aspirants in Bougainville. No one has any similar entities or relationships with any landowners, even in non-prospective areas, and certainly nothing in Panguna, Mainoki, and Karato, described as the three most important mining areas of Bougainville. That said, Numa Numa also continues to develop a road system in Bougainville’s roadless mining region, a limestone quarry and calcination facility to supply lime to all of Bougainville’s mining operations, and an integrated electric utility to supply electricity to Bougainville.

Metals Market Opportunity

The Panguna Mine contains one of the world’s largest copper and gold ore bodies, but the size of the mine’s resource is only one of its favorable characteristics. The amount of resources in the Panguna Mine are beyond dispute. The mine’s reserves are proven, while most of the world’s major deposits waiting to be mined are not. The Panguna Mine itself is highly accessible and comes with developed infrastructure; much of the roads, port facilities, and other infrastructure built to service the Panguna Mine remain largely intact.

The Panguna Mine’s two most important metals—gold and copper—are, at current market prices, almost equally valuable. Together, the mine’s proven gold and copper resources underscore its role as a global tier-one asset.

Panguna’s 547.15 metric tons of known gold reserves equate to nearly 1% of all global reserves, with value estimates exceeding $40 billion. Given the growing interest by many nations in denominating their trade balances in something other than U.S. dollars, the price of gold has increased dramatically over the last two years, and no end is in sight.

As for copper, the global transition to electrification is triggering historic demand for it, yet the supply pipeline is critically constrained. According to RBC Dominion Securities, just four new large-scale copper mines are in development globally, while demand requires at least one new mine per year through 2035. The Panguna Mine’s copper reserves total 5.3 million metric tons—equal to roughly 70% of Canada’s total reserves—placing it in the same league as major copper-producing nations. With ore grades declining and permitting delays mounting worldwide, the Panguna Mine—let alone Mainoki and Karato when they are explored—is uniquely positioned to help fill the world’s looming copper supply gap.

Independence Requires Numa Numa Rebuilding the Panguna Mine—and Diplomacy

Bougainville is currently an autonomous region of Papua New Guinea, but the 2001 Bougainville Peace Agreement provided Bougainville with the right, within 20 years, to conduct an independence referendum. During this period, Bougainville’s current president, Ishmael Toroama, was the lead proponent in advocating Bougainvillean independence. In 2019, the independence referendum, in which registered Bougainvilleans were asked whether they wished to remain part of Papua New Guinea or become citizens of a new, independent country, was held, and 97.7% of the population chose independence. The next year, Ishmael Toroama was elected President of Bougainville.

Numa Numa assisted Toroama in both his independence initiatives and his presidential election. Both Numa Numa and President Toroama, as well as the great majority of Bougainvilleans, understand that Bougainvillean independence depends on having the means to pay for its cost.

Simply put, Bougainvillean independence depends on rebuilding the Panguna Mine. Bougainvilleans know that they cannot do it themselves. The people understand that, and identify Numa Numa’s business plan for rebuilding the Panguna Mine, as well as the support they assume will come from its Western affiliations—most of the company’s shareholders are either American or Canadian—as the key to not only their prosperity, but their freedom as well.

Bougainvilleans also back Numa Numa’s business plan because they fear the alternative: China, which covets not only Bougainville’s gold and copper, but its strategic location together with its deepwater port at Loloho, the best deepwater port in the Third Island Chain.

On the front line in the Western Pacific’s rising tensions between China and the U.S., Bougainvilleans far prefer an alliance with their tradition Western allies to a takeover by China. Numa Numa’s ongoing diplomatic engagement, including arranging recent visits to Washington D.C. with President Ishmael Toroama, positions the company as both an economic and strategic partner in shaping Bougainville’s future.

Leadership Team

John D. Kuhns, Chairman & Chief Executive Officer, founded Numa Numa Resources and has led the company since its formation in 2016. He previously founded China Hydroelectric Corporation, the largest foreign-owned electric power company in China, and listed the company on the NYSE. He has taken five other infrastructure and energy companies from initial concept to public listings and has owned and managed three Wall Street investment firms. He holds degrees from Georgetown University, the University of Chicago, and Harvard Business School and is also the author of four published novels.

Shadron L. Stastney, Vice-Chairman & Chief Operating Officer, joined Numa Numa Resources as a consultant in 2022 and became its Vice-Chairman and Chief Operating Officer in 2025. He was previously the co-founder of Vicis Capital, a multi-strategy hedge fund with peak assets of $6.8 billion. Before that, he was a Director and Head of the Hedging and Monetization Group at Credit Suisse First Boston, and a corporate attorney at Cravath, Swaine and Moore. He received his JD from Yale Law School and his BA from the University of North Dakota.

Anthony Dixon, Director, founded and was the CEO of Helios Renewable Energy Limited, a solar energy developer, and Metanoia, a sustainability auditor. He is also the Founder and Chairman of The Alliance for Sustainable Schools. His previous roles include CEO of ASB Biodiesel, Senior Advisor for Project Development in Asia with Canadian Solar; a Director of China Hydroelectric Corporation; Chief Operating Officer of ZEDFactory; and a Director of the Solar Electric Light Company. He was a Managing Director and Head of UK Capital Markets with Citigroup Global Markets; a Vice President with Salomon Brothers; and Director of Nikko Salomon Smith Barney in Tokyo, where he co-headed the firms’ securitization business. He holds a first-class honors degree in physics and a B.A. in philosophy from the University of Western Australia, an MBA from Harvard Business School, and a master’s degree in renewable energy engineering from Imperial College, London.

Mary E. Fellows, Director, has more than two decades of experience in renewable energy and infrastructure development. She previously served as EVP, Chief Compliance Officer, and Corporate Secretary of China Hydroelectric Corporation, and held leadership roles at GenSelf Corporation, Solar Electric Light Company, and New World Power Corporation. She holds a bachelor’s degree from Teikyo Post University and is a graduate of Harvard Business School’s AMP program.

Ian Smith, Director, is a mining engineering honors graduate from the University of Queensland, Australia. He has 60 years’ experience in the international mining industry, spanning functions including corporate management, operations, project management and engineering. Significantly, he was involved with the development of Bougainville’s Panguna copper-gold mine, from exploration, pre-production and startup to full production. The Panguna Mine at the time was the largest open pit copper-gold mine in the world. He was mine manager until he took another corporate responsibility in Mexico to develop the 72,000tpd La Caridad open pit copper mine. Additional operations and engineering experience include the 2,500 tpd CIL gold project in Uruguay and mining projects in Asia, South America, Africa, and the Pacific Rim.

Lawrence Queen, Senior Consulting Geologist, has over 35 years of experience in global mineral exploration, including five years as Principal Economic Geologist for the Geological Survey of Papua New Guinea. He holds a BSc from the New Mexico Institute of Mining and Technology and an MSc from the University of Alaska and is a long-standing member of both the Australasian Institute of Mining and Metallurgy and the Australian Institute of Geoscientists.

Tete Omas, Manager, Lakeville Mines, oversees operations at Numa Numa’s mining subsidiary and brings deep, hands-on experience in gold mining and equipment fabrication. A second-generation miner, he previously served in the PNG Mineral Resource Authority’s Small Scale Mining Branch and began his career working on his family’s mining lease at Mt. Kaindi.

Seeking Investors: Intention to Go Public Soon

Numa Numa is seeking investors—strategic and financial—to be partners in its world-class, resource-rich Bougainville opportunity. The company’s goal is to not only be the leading mining entity in Bougainville, but to become the country’s leading commercial enterprise as well.

Numa Numa is currently a privately held corporation but is exploring means of going public so as to list its shares on one or more international stock exchanges and provide its shareholders with liquidity.

Recent News

• Numa Numa Resources Inc. - DR Congo Resumes Exports of Cobalt After Lengthy Ban
• Numa Numa Resources Inc. and Why Panguna Remains One of Pacific’s Biggest Prizes
• InvestorNewsBreaks – Numa Numa Resources Inc. Poised as Copper Supply Tightens, Prices Rise

Frontieras North America Inc.

The QualityStocks Daily Newsletter would like to spotlight Frontieras North America Inc.

Frontieras North America, an energy and environmental technology company commercializing its patented FASForm(TM) Solid Carbon Fractionation process, announced it will host a groundbreaking ceremony on April 2, 2026, for its first commercial facility in Mason County, West Virginia. The estimated $850 million industrial project is expected to create approximately 300 full-time jobs with wages averaging three times the area’s average income, along with about 2,000 construction jobs during the build phase. The ceremony, scheduled for 11:30 a.m. ET, will include remarks from company leadership and federal and state officials, followed by a ceremonial groundbreaking. The company’s FASForm(TM) technology is designed to convert coal and other hydrocarbons into fuels and products such as liquid fuels, hydrogen, fertilizer inputs and industrial carbon through a closed-loop process that captures and repurposes byproducts. 

To view the full press release, visit https://ibn.fm/KZ7q1

Frontieras North America Inc. is an energy and environmental technology company focused on redefining how coal and other solid hydrocarbons are utilized within modern energy and industrial systems. Rather than treating coal as a fuel to be burned, the company applies patented processing technology to reform solid hydrocarbons into multiple market-ready energy and industrial products designed for existing global markets.

The company’s approach is rooted in extracting greater value from abundant natural resources through industrial innovation, addressing inefficiencies historically associated with conventional coal use. By separating coal into gases, liquids, and purified solid carbon, Frontieras positions coal as a versatile feedstock capable of supporting transportation, manufacturing, agriculture, and industrial infrastructure demand.

Frontieras emphasizes closed-loop, zero-waste processing as a means of producing energy products more efficiently while reducing emissions and unused byproducts.

Products and Projects

Frontieras’ core platform is FASForm™, a patented Solid Carbon Fractionation process that deconstructs coal by extracting volatiles, moisture, and contaminants. The process produces hydrogen, methane, naphtha, diesel, aviation fuel, and FASCarbon™, a low-sulfur technical carbon product.

The company is developing its first commercial-scale FASForm™ facility in Mason County, West Virginia, an estimated $850 million project designed to process approximately 7,500 tons of coal per day, or about 2.7 million tons annually. The facility is supported by a 10-year feedstock MOU using Pittsburgh #8 coal and a 10-year offtake LOI covering 100% of produced fuels, FASCarbon™, sulfuric acid, and fertilizer.

Engineering, construction, operations, logistics, and insurance partners are under executed agreements, and the project has completed FEL 1 and FEL 2, with substantial FEL 3 underway. Following its initial Mason County development, Frontieras plans to deploy additional FASForm™ facilities in West Virginia, Texas, and Wyoming, with longer-term international deployment in markets where its patent portfolio is in force.

Market Opportunity

Frontieras targets established global energy and chemicals markets with a combined estimated value exceeding $2.1 trillion. The company’s product portfolio aligns with large, existing demand across diesel, hydrogen, naphtha, jet fuel, technical carbon – coke, industrial chemicals, and fertilizer markets. These products are core industrial inputs with long-established supply chains, entrenched end-use applications, and global pricing benchmarks, reducing reliance on the creation of new or speculative markets.

These markets serve essential roles across transportation, agriculture, industrial machinery, aviation, steel manufacturing, petrochemicals, and food production, supporting continuous demand driven by infrastructure, manufacturing, and population growth. The planned design capacity of the first FASForm™ facility is approximately 7,500 tons per day, or about 2.7 million tons annually — equivalent to roughly 0.5% of current U.S. coal production. This design framework is intended to enable Frontieras to scale output incrementally while remaining aligned with existing market capacity, logistics networks, and demand profiles.

Leadership Team

Matthew McKean, Co-Founder & Chief Executive Officer, leads Frontieras’ overall strategy and execution and brings more than 25 years of experience across finance, operations, and business leadership. He previously co-founded a mortgage banking firm that grew into one of the largest originators in the southwestern U.S. before a successful exit, followed by senior leadership roles within large real estate finance organizations. McKean has been an active member of the CEO mentoring organization Vistage, advising companies across construction, finance, infrastructure, and consumer sectors. He holds a Bachelor of Science in Human Nutrition with an emphasis in Chemistry from Arizona State University and completed pre-med coursework.

Josephe Witherspoon, P.E., Co-Founder & Chief Technology Officer, is the inventor of the FASForm™ process and the author of the company’s core patents. He brings extensive experience in petroleum refining, natural gas processing, and chemical engineering from senior roles at Chevron, Enterprise Products, Sinclair Oil, and Marathon Petroleum. As a Process Design Engineer and Major Capital Project Manager, Witherspoon has led projects delivering significant operational and economic improvements. He holds a Bachelor of Science in Chemical and Fuels Engineering from the University of Utah and is a licensed Professional Engineer.

Andrea Moran, Chief Commercial Officer, oversees Frontieras’ commercialization strategy, capital formation, and go-to-market execution. She brings more than 25 years of experience in operations, management, and business development across the energy and infrastructure sectors. Prior to Frontieras, Moran served as Co-Founder and Vice President of Business Development at Yield Power Group, a project finance firm supporting energy and infrastructure projects ranging from $100 million to over $1 billion. She holds a Bachelor of Science in Political Science from the University of Wisconsin and serves on philanthropic and advisory boards.

José López, Chief Financial Officer, leads Frontieras’ financial strategy, operations, and capital planning. He brings over 20 years of experience in global finance and accounting, including senior roles at multinational public companies. López began his career at PwC’s external assurance practice, working across Houston, London, and The Hague. His background includes SEC reporting, corporate governance, FP&A, mergers and acquisitions, and capital markets transactions. He holds a Bachelor of Science in Accounting and Finance from the University of Houston–Clear Lake and is a licensed Certified Public Accountant.

Recent News

• Frontieras North America Inc. - InvestorNewsBreaks – Frontieras North America to Host Groundbreaking for West Virginia Commercial Facility
• InvestorNewsBreaks – Frontieras North America Advances Clean Coal Revival With $850M West Virginia FASForm(TM) Facility
• How Frontieras North America Is Expanding Access to Early-Stage Energy Investment

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms. The partnership will combine HeartBeam’s patented ECG platform, which captures the heart’s electrical activity from three non-coplanar dimensions, with Mount Sinai’s clinically annotated 12-lead ECG datasets and artificial intelligence expertise to advance AI-driven cardiac monitoring. By leveraging longitudinal, high-fidelity synthesized 12-lead ECG data collected from patients in home settings alongside Mount Sinai’s clinical data resources, the collaboration aims to accelerate the training and validation of AI models designed to support personalized cardiac insights, expand potential clinical indications and enable broader applications in preventive cardiology, chronic disease management and remote patient monitoring.

To view the full press release, visit https://ibn.fm/gKzvQ

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company pioneering a new approach to cardiac care by delivering hospital-grade electrocardiogram (ECG) insights outside traditional clinical settings. Its proprietary platform supports a scalable app-based solution for real-time heart monitoring.

The company’s mission is to empower both patients and physicians with actionable cardiac data wherever symptoms begin, addressing a critical gap in the first hours of cardiac events. Through its connected cardiac care ecosystem, HeartBeam is establishing a new model for remote monitoring that deepens patient engagement and delivers more actionable insights for physicians. This approach is designed to obtain early diagnosis which could reduce time to treatment, improve outcomes, and lower costs across the healthcare continuum.

HeartBeam’s system aims to bring clinical-grade cardiac assessment into the home. HeartBeam is preparing for commercial launch as its 12-lead ECG synthesis software undergoes regulatory review, building on prior clearance of its 3D ECG system for arrhythmia assessment. The company plans to leverage its unique longitudinal ECG dataset and deep learning algorithms to advance predictive capabilities in the future.

HeartBeam is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship innovation is its credit card-sized, cable-free ECG device that collects heart signals in three non-coplanar dimensions and synthesizes a 12-lead ECG. Cleared by the FDA in December 2024 for arrhythmia assessment, the HeartBeam System enables patients to capture high-fidelity heart data during symptomatic episodes, even outside a clinical environment.

The company’s pending 12-lead ECG synthesis software, developed from the same 3D signal acquisition, successfully met clinical endpoints in the VALID-ECG study and is currently under FDA review for arrhythmia assessment. This software combined with an on-demand cardiologist reader service is expected to form the backbone of HeartBeam’s commercial launch strategy, providing patients with access to a synthesized 12-lead ECG outside of the traditional hospital setting and enabling physician interpretation of patient ECGs from anywhere.

From the core, the team is building an ecosystem that includes integration with wearables, automated arrhythmia assessments, AI-driven wellness features, community features and trending insights. The ecosystem is intended to drive adoption and increase the overall value of the HeartBeam System.

Artificial Intelligence and Predictive Analytics

To enhance its diagnostic capabilities, HeartBeam is developing AI-powered arrhythmia detection algorithms to be validated in collaboration with Mount Sinai Heart. In early testing, these deep learning algorithms achieved diagnostic accuracy comparable to standard 12-lead ECGs when classifying atrial fibrillation, atrial flutter, and sinus rhythm.

Additionally, HeartBeam’s AI engine has the potential to transform routine monitoring into predictive power in the future. The company’s platform enables frequent readings, building a unique longitudinal ECG dataset unique that no one else offers. By leveraging deep learning on the repeated measurements, there is an opportunity to develop predictive capabilities, such as screening for hidden cardiac conditions and forecasting risk of future events. The unique longitudinal dataset will create a defensible data moat as the company continues to advance its AI program.

Market Opportunity

HeartBeam is targeting a large unmet need in cardiac care by delivering hospital-grade ECG diagnostics to patients outside of traditional healthcare settings. Cardiovascular disease is the leading cause of death worldwide, yet most cardiac events occur at home, where standard 12-lead ECGs are not available, leading to costly delays in diagnosis and treatment. HeartBeam’s FDA-cleared 3D ECG technology is designed to close this critical gap with on-demand, remote diagnostic capabilities.

The company’s initial commercialization strategy focuses on two distinct U.S. entry markets. The first includes approximately 500,000 elevated-risk patients in concierge care settings, representing a $250 million to $500 million annual revenue opportunity. The second addresses a larger direct-pay segment of 2.6 million elevated-risk individuals, with potential revenues of $1.3 billion to $2.6 billion annually. Future expansion may include reimbursement-driven pathways through Medicare Advantage, providers, and payer partnerships.

HeartBeam anticipates annual subscription pricing between $500 and $1,000 per patient, with roughly 50% gross margins on device costs and 70%+ on recurring revenue. Based on a model using five U.S. regions, each with an estimated 75,000 eligible patients, HeartBeam projects that just 10% adoption would generate approximately $20 million in gross profit—enough to reach cash flow break-even under current pricing and margin assumptions. Over time, the company’s longitudinal ECG dataset and predictive AI capabilities are expected to deliver additional value to healthcare systems, research institutions, and life science partners.

Leadership Team

Robert Eno, Chief Executive Officer and Director, brings over 30 years of experience in the medical technology industry, including leadership roles at HeartFlow, OptiMedica, and NeoGuide Systems. He joined HeartBeam as President in January 2023 and was appointed CEO in October 2024, later joining the board in May 2025 to support commercial growth.

Branislav Vajdic, Ph.D., Founder and Chief Technology Officer, is a semiconductor and medtech innovator who previously led product design teams at Intel and founded NewCardio. He holds over 20 patents and is the original architect of HeartBeam’s core technology.

Tim Cruickshank, Chief Financial Officer, oversees financial strategy and capital allocation. He works closely with the leadership team to support commercialization while maintaining financial discipline aligned with key regulatory milestones.

Peter Fitzgerald, M.D., Ph.D., Chief Medical Advisor, is Director of the Center for Cardiovascular Technology at Stanford and a seasoned clinical trialist with over 175 studies and 650 publications. He has founded over 20 medtech companies and advises the FDA on digital health analytics.

Ken Persen, Chief Technology Officer, has more than 28 years of experience in cardiac rhythm management and digital health. He previously served as CTO and CEO at LIVMOR and held engineering roles at Cameron Health and Guidant.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $1.35, off by 8.7838%, on 32,885,545 volume. The average volume for the last 3 months is 1,860,173 and the stock's 52-week low/high is $0.54/$4.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Collaborates With Mount Sinai to Advance AI-ECG Algorithm Development
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Schedules March 12 Conference Call to Review Q4 and Full-Year 2025 Results
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in ALIGN-ACS Pilot Study for Heart Attack Detection